Age-Related Macular Degeneration (ARMD) Completed Phase 3 Trials for Ranibizumab (DB01270)

Also known as: Age-related macular degeneration / Macular Degeneration / Senile macular degeneration / Macular degeneration senile / Macular degeneration (senile) of retina, unspecified

IndicationStatusPhase
DBCOND0034150 (Age-Related Macular Degeneration (ARMD))Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01948830Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMDSupportive Care
NCT00891735A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)Treatment
NCT00251459A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)Treatment
NCT00429962Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNVTreatment
NCT00470678EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)Treatment